Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients With Brain Metastases

NCT06764940 is registered in ClinicalTrials.gov with Biostar Pharma, Inc. as lead sponsor.

NCT NCT06764940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06764940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients With Brain Metastases
Lead sponsor
Biostar Pharma, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 14, 2025
Completion date
July 15, 2027
Enrollment
120 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer patients with brain metastases